MTB-9655 / Metabomed - LARVOL DELTA

Phase 1 first-in-human trial of MTB-9655, the first oral inhibitor of ACSS2, in patients with advanced solid tumors. (ASCO 2022) - P1 | "MTB-9655 has been well tolerated, and the safety profile was predictable based on preclinical studies in rodents and non-human primates. Dose proportional plasma drug levels were observed and predicted to have reached biologically active levels. Expected increase in bilirubin levels was observed in 1 patient, which may be used as a marker of significant drug exposure."

Clinical • P1 data • Breast Cancer • Colorectal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor